{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:37:42Z","timestamp":1784068662797,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40261-025-01454-7","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T06:09:25Z","timestamp":1751090965000},"page":"565-574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Cost-Effectiveness Analysis of Rivaroxaban Compared to Warfarin for the Management of Venous Thromboembolism in Western Kenya"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8071-7997","authenticated-orcid":false,"given":"Emily T.","family":"O\u2019Neill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Wilson-Barthes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Manji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Kigen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naftali","family":"Busakhala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Nyanje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Gal\u00e1rraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonak D.","family":"Pastakia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,28]]},"reference":[{"issue":"Suppl 1","key":"1454_CR1","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1016\/j.thromres.2018.01.028","volume":"164","author":"GH Lyman","year":"2018","unstructured":"Lyman GH, Culakova E, Poniewierski MS, Kuderer NM. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res. 2018;164(Suppl 1):S112\u20138.","journal-title":"Thromb Res"},{"issue":"11","key":"1454_CR2","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1161\/ATVBAHA.114.304488","volume":"34","author":"GE Raskob","year":"2014","unstructured":"Raskob GE, Angchaisuksiri P, Blanco AN, et al. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014;34(11):2363\u201371.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"1454_CR3","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.3390\/jcm9082467","volume":"9","author":"M Nicholson","year":"2020","unstructured":"Nicholson M, Chan N, Bhagirath V, Ginsberg J. Prevention of venous thromboembolism in 2020 and beyond. J Clin Med. 2020;9(8):2467.","journal-title":"J Clin Med"},{"issue":"20","key":"1454_CR4","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1161\/CIRCULATIONAHA.115.019310","volume":"132","author":"M Blondon","year":"2015","unstructured":"Blondon M, Bounameaux H. Secondary prevention of venous thromboembolism: one regimen may not fit all. Circulation. 2015;132(20):1856\u20139.","journal-title":"Circulation"},{"issue":"26","key":"1454_CR5","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1056\/NEJM199106273242606","volume":"324","author":"J Hirsh","year":"1991","unstructured":"Hirsh J. Oral anticoagulant drugs. N Engl J Med. 1991;324(26):1865\u201375.","journal-title":"N Engl J Med"},{"issue":"7","key":"1454_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.16009","volume":"4","author":"CC Kamath","year":"2021","unstructured":"Kamath CC, Giblon R, Kunneman M, et al. Cost conversations about anticoagulation between patients with atrial fibrillation and their clinicians: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2021;4(7): e2116009-e.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1454_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ahj.2015.03.017","volume":"170","author":"SD Pokorney","year":"2015","unstructured":"Pokorney SD, Simon DN, Thomas L, et al. Patients\u2019 time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J. 2015;170(1):141\u20138 (8.e1).","journal-title":"Am Heart J"},{"issue":"4","key":"1454_CR8","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1097\/MLR.0000000000001253","volume":"58","author":"A Garc\u00eda-Sempere","year":"2020","unstructured":"Garc\u00eda-Sempere A, Hurtado I, Bejarano D, et al. Group-based trajectory models to assess quality of INR control and its association with clinical outcomes. Med Care. 2020;58(4):e23\u201330.","journal-title":"Med Care"},{"issue":"8","key":"1454_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.28033","volume":"6","author":"MC Fang","year":"2023","unstructured":"Fang MC, Reynolds K, Fan D, et al. Clinical outcomes of direct oral anticoagulants vs warfarin for extended treatment of venous thromboembolism. JAMA Netw Open. 2023;6(8): e2328033-e.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"1454_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/MBC.0000000000000800","volume":"30","author":"AT Cohen","year":"2019","unstructured":"Cohen AT, Bauersachs R. Rivaroxaban and the EINSTEIN clinical trial programme. Blood Coagul Fibrinolysis. 2019;30(3):85\u201395.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"1454_CR11","doi-asserted-by":"publisher","first-page":"107602962311842","DOI":"10.1177\/10760296231184216","volume":"29","author":"D Njuguna","year":"2023","unstructured":"Njuguna D, Nwaneri F, Prichard AC, et al. Risk of bleeding associated with outpatient use of rivaroxaban in VTE management at a National Referral Hospital in Western Kenya. Clin Appl Thromb Hemost. 2023;29:10760296231184216.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"1454_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/ejh.13185","volume":"102","author":"CG Kohn","year":"2019","unstructured":"Kohn CG, Bunz TJ, Beyer-Westendorf J, Coleman CI. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism. Eur J Haematol. 2019;102(2):143\u20139.","journal-title":"Eur J Haematol"},{"issue":"4","key":"1454_CR13","doi-asserted-by":"publisher","first-page":"186","DOI":"10.5830\/CVJA-2021-060","volume":"33","author":"A Obayo","year":"2022","unstructured":"Obayo A, Ngunga M, Shah J, Sokwala A, Barasa A. Bleeding complications in patients on new oral anticoagulants for venous thromboembolism in Kenya. Cardiovasc J Afr. 2022;33(4):186\u201392.","journal-title":"Cardiovasc J Afr"},{"key":"1454_CR14","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/CEOR.S327868","volume":"13","author":"MT Derseh","year":"2021","unstructured":"Derseh MT, Solomon K, Tamene W, Beneberu W, Yayehrad AT, Ambaye AS. A cost effectiveness analysis of rivaroxaban compared to warfarin for deep vein thrombosis (DVT) treatment in Ethiopia. Clinicoecon Outcomes Res. 2021;13:821\u201334.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"19","key":"1454_CR15","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1001\/archinternmed.2010.367","volume":"170","author":"A Iorio","year":"2010","unstructured":"Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med. 2010;170(19):1710\u20136.","journal-title":"Arch Intern Med"},{"key":"1454_CR16","unstructured":"Alarid-Escudero F, Krijkamp E, Enns EA, et al., editors. A tutorial on time-dependent cohort state-transition models in r using a cost-effectiveness analysis example. 20220916 ed; 2023."},{"issue":"18","key":"1454_CR17","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.jacc.2014.01.069","volume":"63","author":"WJ Kikkert","year":"2014","unstructured":"Kikkert WJ, Geloven NV, Laan MHVD, et al. The Prognostic value of Bleeding Academic Research Consortium (BARC)-defined bleeding\u00a0complications in st-segment elevation myocardial infarction. J Am Coll Cardiol. 2014;63(18):1866\u201375.","journal-title":"J Am Coll Cardiol"},{"key":"1454_CR18","unstructured":"The World Bank. Official exchange rate (LCU per US$, period average)-Kenya. 2022. https:\/\/data.worldbank.org\/indicator\/PA.NUS.FCRF?locations=KE. Accessed 1 Nov 2022."},{"key":"1454_CR19","volume-title":"Making choices in health: WHO guide to cost-effectiveness analysis\/edited by T. Tan-Torres Edejer ... [et al]","year":"2003","unstructured":"World Health O, Baltussen RMPM, Adam T, et al editors. Making choices in health: WHO guide to cost-effectiveness analysis\/edited by T. Tan-Torres Edejer ... [et al]. Geneva: World Health Organization; 2003."},{"issue":"12","key":"1454_CR20","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1001\/jamainternmed.2013.563","volume":"173","author":"K Hogg","year":"2013","unstructured":"Hogg K, Kimpton M, Carrier M, Coyle D, Forgie M, Wells P. Estimating quality of life in acute venous thrombosis. JAMA Intern Med. 2013;173(12):1067\u201372.","journal-title":"JAMA Intern Med"},{"issue":"5","key":"1454_CR21","doi-asserted-by":"publisher","first-page":"615","DOI":"10.20344\/amp.5257","volume":"27","author":"IF Santos","year":"2014","unstructured":"Santos IF, Pereira S, McLeod E, Guillermin AL, Chatzitheofilou I. Economic analysis of rivaroxaban for the treatment and long-term prevention of venous thromboembolism in Portugal. Acta Med Port. 2014;27(5):615\u201324.","journal-title":"Acta Med Port"},{"key":"1454_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12959-015-0051-3","volume":"13","author":"L Bamber","year":"2015","unstructured":"Bamber L, Muston D, McLeod E, Guillermin A, Lowin J, Patel R. Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin\/vitamin K antagonist. Thromb J. 2015;13:20.","journal-title":"Thromb J"},{"issue":"8","key":"1454_CR23","doi-asserted-by":"publisher","first-page":"e1075","DOI":"10.1200\/OP.20.00783","volume":"17","author":"ES Ryan","year":"2021","unstructured":"Ryan ES, Havrilesky LJ, Salinaro JR, Davidson BA. Cost-effectiveness of venous thromboembolism prophylaxis during neoadjuvant chemotherapy for ovarian cancer. JCO Oncol Pract. 2021;17(8):e1075\u201384.","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"1454_CR24","first-page":"1336","volume":"92","author":"M Locadia","year":"2004","unstructured":"Locadia M, Bossuyt PM, Stalmeier PF, et al. Treatment of venous thromboembolism with vitamin K antagonists: patients\u2019 health state valuations and treatment preferences. Thromb Haemost. 2004;92(6):1336\u201341.","journal-title":"Thromb Haemost"},{"key":"1454_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.716224","volume":"12","author":"KX Sun","year":"2021","unstructured":"Sun KX, Cui B, Cao SS, et al. Cost-effectiveness analysis of direct oral anticoagulants versus vitamin K antagonists for venous thromboembolism in China. Front Pharmacol. 2021;12: 716224.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1454_CR26","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/13696998.2019.1582058","volume":"22","author":"RA Bobade","year":"2019","unstructured":"Bobade RA, Helmers RA, Jaeger TM, Odell LJ, Haas DA, Kaplan RS. Time-driven activity-based cost analysis for outpatient anticoagulation therapy: direct costs in a primary care setting with optimal performance. J Med Econ. 2019;22(5):471\u20137.","journal-title":"J Med Econ"},{"key":"1454_CR27","first-page":"5534873","volume":"2021","author":"N Jaberi","year":"2021","unstructured":"Jaberi N, Kavosi Z, Hooshmandi E, Moradi N, Keshavarz K, Borhani-Haghighi A. The Study of cost-effectiveness of rivaroxaban versus warfarin in patients with atrial fibrillation who developed ischemic stroke. Stroke Res Treat. 2021;2021:5534873.","journal-title":"Stroke Res Treat"},{"issue":"1","key":"1454_CR28","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1186\/s12913-019-4711-z","volume":"19","author":"A Leminen","year":"2019","unstructured":"Leminen A, Pyyk\u00f6nen M, Tynkkynen J, Tykkyl\u00e4inen M, Laatikainen T. Modeling patients\u2019 time, travel, and monitoring costs in anticoagulation management: societal savings achievable with the shift from warfarin to direct oral anticoagulants. BMC Health Serv Res. 2019;19(1):901.","journal-title":"BMC Health Serv Res"},{"key":"1454_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.xjon.2023.05.006","volume":"15","author":"MP Pereira","year":"2023","unstructured":"Pereira MP, Lima EG, Pitta FG, et al. Rivaroxaban versus warfarin in postoperative atrial fibrillation: Cost-effectiveness analysis in a single-center, randomized, and prospective trial. JTCVS Open. 2023;15:199\u2013210.","journal-title":"JTCVS Open"},{"issue":"6","key":"1454_CR30","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.thromres.2013.09.015","volume":"132","author":"CD Seaman","year":"2013","unstructured":"Seaman CD, Smith KJ, Ragni MV. Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective. Thromb Res. 2013;132(6):647\u201351.","journal-title":"Thromb Res"},{"issue":"7","key":"1454_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038433","volume":"10","author":"L Yang","year":"2020","unstructured":"Yang L, Wu J. Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China. BMJ Open. 2020;10(7): e038433.","journal-title":"BMJ Open"},{"issue":"3","key":"1454_CR32","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1007\/s12325-022-02422-9","volume":"40","author":"JS Berger","year":"2023","unstructured":"Berger JS, Ashton V, Lalibert\u00e9 F, et al. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population. Adv Ther. 2023;40(3):1224\u201341.","journal-title":"Adv Ther"},{"key":"1454_CR33","doi-asserted-by":"crossref","unstructured":"Margolis JM, Deitelzweig S, Kline J, et al. Shorter hospital stays and lower costs for rivaroxaban compared with warfarin for venous thrombosis admissions. J Am Heart Assoc. 2016; 5(10).","DOI":"10.1161\/JAHA.116.003788"},{"issue":"12","key":"1454_CR34","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1182\/blood-2013-12-512681","volume":"123","author":"C Kearon","year":"2014","unstructured":"Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood. 2014;123(12):1794\u2013801.","journal-title":"Blood"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01454-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01454-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01454-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T23:58:28Z","timestamp":1757203108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01454-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1454"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01454-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,28]]},"assertion":[{"value":"28 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study was not supported by any grants or external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"S.P. reports receiving professional fees from Becton Dickinson for consulting work on philanthropic activities outside the submitted work. E.O. no conflict. A.H. no conflict. M.B. no conflict. I.M. no conflict. G.K. no conflict. N.B. no conflict. S.N. no conflict. O.G. no conflict. The Anticoagulation Clinic obtained rivaroxaban (Xarelto\u00ae) from Bayer East Africa Limited as part of a Rivaroxaban Access Program. There was no contribution (financial or otherwise) from the company in terms of data collection, manuscript writing and submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study did not require ethics approval, as it involved secondary analysis of de-identified, aggregate data and did not involve human subjects. Clinical data used in the analysis were drawn from a previously approved observational study conducted by our research group, which received ethics approval from Moi Teaching and Referral Hospital\u2019s Internal Review Board. No new data were collected, and all analyses complied with national research ethics guidelines in Kenya.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data and code that support the findings of this study are available in a public data repository on GitHub [], DOI reference: .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Clinical data used to determine event rates and ultimately transition state probabilities are available upon request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"E.O. participated in conceiving the study, literature search, data analysis, interpretation of the data, writing and critical revision of the manuscript for important intellectual content, and final approval of the manuscript submitted. S.P. participated in conceiving the study, interpretation of the data, critical revision of the manuscript for important intellectual content, and final approval of the manuscript submitted. A.H. and M.B. participated in data analysis, interpretation of the data, critical revision of the manuscript for important intellectual content, and final approval of the manuscript submitted. I.M., G.K., N.B., S.N., and O.G. participated in interpreting results, providing critical revisions, and final approval of the manuscript. All authors read and approved the final version of manuscript and are accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}